Collegium Pharmaceutical (COLL) Deferred Taxes (2021 - 2026)

Collegium Pharmaceutical's Deferred Taxes history runs 6 years deep, the most recent figure standing at -$968000.0 for Q1 2026.

• On a quarterly basis, Deferred Taxes fell 79.59% year-over-year to -$968000.0 in Q1 2026; TTM through Mar 2026 was -$26.1 million, a 13.71% decrease from a year earlier, with the FY2025 full-year figure at -$25.7 million, up 4.31% from the prior year.
• Deferred Taxes advanced to -$968000.0 in Q1 2026 per COLL's latest filing, from -$10.1 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $2.1 million in Q3 2022 and bottomed at -$12.1 million in Q3 2025.
• The 5-year median for Deferred Taxes is -$2.9 million (2025), against an average of -$3.8 million.
• Across the five-year window, Deferred Taxes jumped 656.23% in 2022 and slumped 9491.3% in 2024, its largest moves.
• Year by year, Deferred Taxes stood at -$1.1 million in 2022, then surged by 68.65% to -$338000.0 in 2023, then slumped by 2904.73% to -$10.2 million in 2024, then gained by 0.83% to -$10.1 million in 2025, then soared by 90.39% to -$968000.0 in 2026.
• Per Business Quant, the three latest COLL Deferred Taxes figures stand at -$968000.0 (Q1 2026), -$10.1 million (Q4 2025), and -$12.1 million (Q3 2025).